News

●       David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in...

● The funding will support Theolytics’ Phase 1 clinical trial for THEO-260 in ovarian cancer and incorporates comprehensive biomarker...

Oxford, UK, 12 July 2024 Today Theolytics, a clinical stage biotechnology company harnessing viruses to combat disease, announced that...

Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science...

Mike brings decades of operational and board experience gained in Pharma, Biotech and Venture Capital to Theolytics Oxford, UK, March...

Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer ahead of first in human clinical trials anticipated

Oxford, UK, 9 June 2023 - Theolytics, a biotechnology company harnessing viruses to combat disease, today announces data presentations at...

Oxford, UK, 6th October 2022 - Theolytics, a biotechnology company harnessing viruses to combat disease, will release data on their...

Theolytics kick-starts a £1M project in collaboration with The University of Sheffield, supported by Innovate UK, to develop a novel...

Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team....

We’re delighted to announce that we’re all taking part in the BioIndustry Association’s Research Relay 2021 to raise money for Ovarian...

Theolytics has been awarded a grant by Innovate UK, the UK’s innovation agency, to optimise their oncolytic virus candidate for treatment...

Theolytics, today announced the Board appointment of Carsten Reinhardt MD PhD. Oxford, UK, 21st September 2020 Theolytics, a biotech...

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies. Oxford,...